InventisBio Co., Limited (SHA:688382)

China flag China · Delayed Price · Currency is CNY
17.19
+0.47 (2.81%)
At close: Jun 18, 2026
Market Cap9.94B -27.5%
Revenue (ttm)71.64M -57.5%
Net Income-303.73M
EPS-0.53
Shares Out 578.35M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume13,099,020
Open16.60
Previous Close16.72
Day's Range16.40 - 17.62
52-Week Range15.78 - 49.68
Beta0.27
AnalystsStrong Buy
Price Target32.55 (+89.35%)
Earnings DateAug 28, 2026

About InventisBio

InventisBio Co., Limited, a clinical stage biotech company, focuses on areas of oncology, autoimmune diseases, and metabolic disorders to address unmet medical needs in China. Its product pipeline for the oncology therapeutic area include Befoternitib (BPI-D0316), which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Garsorasib (D-1553), which is in phase II and III clinical trials to treat NSCLS and colorectal cancer; Taragarestrant (D-0502), which is in phase III and II to treat estrogen receptor positiv... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 182
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688382
Full Company Profile

Financial Performance

In 2025, InventisBio's revenue was 37.29 million, a decrease of -77.91% compared to the previous year's 168.79 million. Losses were -316.87 million, 31.9% more than in 2024.

Financial Statements